Original articles
Xiaomeng Gao, Jieqiong You, Yanling Gong, Meng Yuan, Haiying Zhu, Liang Fang, Hong Zhu, Meidan Ying, Qiaojun He, Bo Yang, Ji Cao. WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1225-1239

WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit
Xiaomeng Gaoa, Jieqiong Youa, Yanling Gonga, Meng Yuana,b, Haiying Zhua, Liang Fangc, Hong Zhua,d, Meidan Yinga,d, Qiaojun Hea,b,d, Bo Yanga,b, Ji Caoa,b,d
a. Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China;
b. The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China;
c. Department of Biology, Southern University of Science and Technology, Shenzhen 518055, China;
d. Cancer Center of Zhejiang University, Hangzhou 310058, China
Abstract:
The dysregulation of transcription factors is widely associated with tumorigenesis. As the most well-defined transcription factor in multiple types of cancer, c-Myc can transform cells by transactivating various downstream genes. Given that there is no effective way to directly inhibit c-Myc, c-Myc targeting strategies hold great potential for cancer therapy. In this study, we found that WSB1, which has a highly positive correlation with c-Myc in 10 cancer cell lines and clinical samples, is a direct target gene of c-Myc, and can positively regulate c-Myc expression, which forms a feedforward circuit promoting cancer development. RNA sequencing results from Bel-7402 cells confirmed that WSB1 promoted c-Myc expression through the β-catenin pathway. Mechanistically, WSB1 affected β-catenin destruction complex-PPP2CA assembly and E3 ubiquitin ligase adaptor β-TRCP recruitment, which inhibited the ubiquitination of β-catenin and transactivated c-Myc. Of interest, the effect of WSB1 on c-Myc was independent of its E3 ligase activity. Moreover, overexpressing WSB1 in the Bel-7402 xenograft model could further strengthen the tumor-driven effect of c-Myc overexpression. Thus, our findings revealed a novel mechanism involved in tumorigenesis in which the WSB1/c-Myc feedforward circuit played an essential role, highlighting a potential c-Myc intervention strategy in cancer treatment.
Key words:    Transcription factors    c-Myc    WSB1    Ubiquitination-proteasome pathway    β-Catenin destruction complex    Feedback loop    Tumorigenesis    Cancer treatment   
Received: 2021-06-28     Revised: 2021-09-13
DOI: 10.1016/j.apsb.2021.10.021
Funds: This work was supported by grants from Zhejiang Provincial Natural Science Foundation (No. Y18H310001 to Ji Cao, China), the National Natural Science Foundation of China (No. 81872885 to Ji Cao; No.81625024 to Bo Yang), and the Talent Project of Zhejiang Association for Science and Technology (No.2018YCGC002 to Ji Cao, China).
Corresponding author: Ji Cao,E-mai:caoji88@zju.edu.cn     Email:caoji88@zju.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Xiaomeng Gao
Jieqiong You
Yanling Gong
Meng Yuan
Haiying Zhu
Liang Fang
Hong Zhu
Meidan Ying
Qiaojun He
Bo Yang
Ji Cao

References:
[1] Maston GA, Evans SK, Green MR. Transcriptional regulatory elements in the human genome. Annu Rev Genom Hum Genet 2006;7:29-59
[2] Gonzalez-Nunez V, Rodriguez RE. Chapter 12-cocaine and transcription factors. In: Preedy VR, Editor. The neuroscience of cocaine. San Diego: Academic Press 2017. p. 107-124
[3] Darnell JE Jr Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-749
[4] Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell 2017;168:629-643
[5] Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11
[6] Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016;352:227-231
[7] Lutz W, Leon J, Eilers M. Contributions of myc to tumorigenesis. Biochim Biophys Acta 2002;1602:61-71
[8] Bidwell GL 3rd, Davis AN, Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Contr Release 2009;135:2-10
[9] Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-917
[10] Dean M, Kent RB, Sonenshein GE. Transcriptional activation of immunoglobulin alpha heavy-chain genes by translocation of the c-myc oncogene. Nature 1983;305:443-446
[11] Levens D. You don't muck with MYC. Genes Cancer 2010;1:547-554
[12] MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26
[13] He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512
[14] Zhang S, Li Y, Wu Y, Shi K, Bing L, Hao J. Wnt/β-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells. Anat Rec 2012;295:2104-2113
[15] Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet 2005; 37 Suppl: S31-S37
[16] Kim JJ, Lee SB, Yi SY, Han SA, Kim SH, Lee JM, et al. WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation. Cell Res 2017;27:274-293
[17] Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009;37:4587-4602
[18] Haque M, Kendal JK, MacIsaac RM, Demetrick DJ. WSB1: from homeostasis to hypoxia. J Biomed Sci 2016;23:61
[19] Poujade FA, Mannion A, Brittain N, Theodosi A, Beeby E, Leszczynska KB, et al. WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer. Br J Cancer 2018;118:1229-1237
[20] Choi DW, Seo YM, Kim EA, Sung KS, Ahn JW, Park SJ, et al. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1. J Biol Chem 2008;283:4682-4689
[21] Cao J, Wang Y, Dong R, Lin G, Zhang N, Wang J, et al. Hypoxia-induced WSB1 promotes the metastatic potential of osteosarcoma cells. Cancer Res 2015;75:4839-4851
[22] Liao P, Wang W, Shen M, Pan W, Zhang K, Wang R, et al. A positive feedback loop between EBP2 and c-Myc regulates rDNA transcription, cell proliferation, and tumorigenesis. Cell Death Dis 2014;5:e1032
[23] Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 2008;68:5326-5334
[24] Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006;103:18261-18266
[25] Liu X, Rubin JS, Kimmel AR. Rapid, Wnt-induced changes in GSK3β associations that regulate β-catenin stabilization are mediated by Gα proteins. Curr Biol 2005;15:1989-1997
[26] Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol 2005;7:698-705
[27] Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 1985;318:69-73
[28] van Kappel EC, Maurice MM. Molecular regulation and pharmacological targeting of the β-catenin destruction complex. Br J Pharmacol 2017;174:4575-4588
[29] Harb J, Lin PJ, Hao J. Recent development of Wnt signaling pathway inhibitors for cancer therapeutics. Curr Oncol Rep 2019;21:12
[30] Abitbol S, Dahmani R, Coulouarn C, Ragazzon B, Mlecnik B, Senni N, et al. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation. J Hepatol 2018;68:1203-1213
[31] Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007;26:774-780
[32] Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem 1999;274:3439-3445
[33] Thompson JJ, Williams CS. Protein phosphatase 2A in the regulation of Wnt signaling, stem cells, and cancer. Genes 2018;9:121
[34] Ratcliffe MJ, Itoh K, Sokol SY. A positive role for the PP2A catalytic subunit in Wnt signal transduction. J Biol Chem 2000;275:35680-35683
[35] Posternak V, Cole MD. Strategically targeting MYC in cancer. F1000Res 2016;5: F1000 Faculty Rev-408
[36] Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 2017;171:1284-1300.e21
[37] Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol 2010;2:16-20
[38] Thomas LR, Tansey WP. Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res 2011;110:77-106
[39] Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 2004;3:1133-1137
[40] Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 2008;8:369
[41] Malz M, Bovet M, Samarin J, Rabenhorst U, Sticht C, Bissinger M, et al. Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. Hepatology 2014;60:1241-1250
[42] Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012;151:68-79
[43] Cliff TS, Wu T, Boward BR, Yin A, Yin H, Glushka JN, et al. MYC controls human pluripotent stem cell fate decisions through regulation of metabolic flux. Cell Stem Cell 2017;21:502-516.e9
[44] Kim SE, Huang H, Zhao M, Zhang X, Zhang A, Semonov MV, et al. Wnt stabilization of β-catenin reveals principles for morphogen receptor-scaffold assemblies. Science 2013;340:867-870
[45] Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 1999;274:10681-10684
Similar articles: